New antithrombotic drugs

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 2, 2009, Pages 139-146

  Gross, P L ^a   Weitz, J I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; ATAZANAVIR; AVIDIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CANGRELOR; CILOSTAZOL; CLARITHROMYCIN; CLOPIDOGREL; DABIGATRAN ETEXILATE; DIPYRIDAMOLE; E 5555; ENOXAPARIN; IDRABIOTAPARINUX; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; QUINIDINE; RIVAROXABAN; SCH 530348; THROMBIN INHIBITOR; THROMBOXANE A2; TICAGRELOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ARTERY THROMBOSIS; BLOOD CLOTTING; CLINICAL TRIAL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; ISCHEMIA; KIDNEY CLEARANCE; LIVER TOXICITY; LUNG EMBOLISM; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; ANTITHROMBIN III; DRUG DESIGN; FIBRINOLYTIC AGENTS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INFLAMMATION; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; RECEPTOR, PAR-1; RECEPTORS, PURINERGIC P2; THROMBIN; THROMBOXANE A2; VITAMIN K;

EID: 67651227144     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.98     Document Type: Review

References (74)

1. Wolf, P.A., Abbott, R.D. & Kannel, W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch. Intern. Med. 147, 1561-1564 (1987).
2. Coombes, R. Venous thromboembolism caused 25,000 deaths a year, say MPs. BMJ 330, 559 (2005).
3. López, J.A., Kearon, C. & Lee, A.Y. Deep venous thrombosis. Hematology Am. Soc. Hematol. Educ. Program 439-456 (2004).
4. Freiman, D.G. The structure of thrombi. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice (eds. Colman, R.W., Hirsh, J., Marder, V.J. & Salzman, E.) 766-780 (JB Lippincott, Philadelphia, 1987).
5. Becker, R.C. et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (6 suppl.), 776S-814S (2008).
6. Goodman, S.G., Menon, V., Cannon, C.P., Steg, G., Ohman, E.M. & Harrington R.A. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (6 suppl.), 708S-775S (2008).
7. Anand, S.S. & Yusuf, S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 282, 2058-2067 (1999).
8. Geerts, W.H. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (6 suppl.), 381S-453S (2008).
9. Kearon, C., Kahn, S.R., Agnelli, G., Goldhaber, S., Raskob, G.E. & Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (6 suppl.), 454S-545S (2008).
10. Hovens, M.M., Snoep, J.D., Tamsma, J.T. & Huisman, M.V. Aspirin in the prevention and treatment of venous thromboembolism. J. Thromb. Haemost. 4, 1470-1475 (2006).
11. Mewissen, M.W., Seabrook, G.R., Meissner, M.H., Cynamon, J., Labropoulos, N. & Haughton, S.H. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 211, 39-49 (1999).
12. Bhatt, D.L. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706-1717 (2006).
13. Meadows, T.A. & Bhatt, D.L. Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res. 100, 1261-1275 (2007).
14. Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A. & Hylek, E. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 26 (3 suppl.), 204S-233S (2004).
15. Go, A.S., Hylek, E.M., Borowsky, L.H., Phillips, K.A., Selby, J.V. & Singer, D.E. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann. Intern. Med. 131, 927-934 (1999).
16. Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. & Palareti, G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (6 suppl.), 160S-198S (2008).
17. Moscucci, M. et al. Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur. Heart J. 24, 1815-1823 (2003).
18. Yusuf, S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 354, 1464-1476 (2006).
19. Sobieraj-Teague, M., Gallus, A.S. & Eikelboom, J.W. The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. Curr. Opin. Cardiol. 23, 327-334 (2008).
20. Ruggeri, Z.M. Platelets in atherothrombosis. Nat. Med. 8, 1227-1234 (2002).
21. Mackman, N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol. Dis. 36, 104-107 (2006).
22. Bouchard, B.A., Butenas, S., Mann, K.G. & Tracey, P.B. Interaction between platelets and the coagulation system. In Platelets 2nd edn. (ed. Michelson, A.D.) 377-402 (Academic Press, New York, 2007).
23. Ruggeri, Z.M. & Mendolicchio, G.L. Adhesion mechanisms in platelet function. Circ. Res. 100, 1673-1685 (2007).
24. Vane, J.R., Bakhle, Y.S. & Botting, R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38, 97-120 (1998).
25. Hankey, G.J. & Eikelboom, J.W. Aspirin resistance. Lancet 367, 606-617 (2006).
26. Eikelboom, J.W. et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 118, 1705-1712 (2008).
27. Gaussem, P. et al. The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J. Thromb. Haemost. 3, 1437-1445 (2005).
28. Fitzgerald, D.J., Fragetta, J. & FitzGerald, G.A. Prostaglandin endoperoxides modulates the response to thromboxane synthase inhibition during coronary thrombosis. J. Clin. Invest. 82, 1708-1713 (1988).
29. Ghuysen, A. et al. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. Cardiovasc. Drug Rev. 23, 1-14 (2005).
30. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 89, 588-595 (1994).
31. Dorsam, R.T. & Kunapuli, S.P. Central role of the P2Y12 receptor in platelet activation. J. Clin. Invest. 113, 340-345 (2004).
32. Cairns, J.A. & Eikelboom, J. Clopidogrel resistance: more grist for the mill. J. Am. Coll. Cardiol. 51, 1935-1937 (2008).
33. Brandt, J.T. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 2429-2436 (2007).
34. Trenk, D. et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol. 51, 1925-1934 (2008).
35. Lau, W.C. & Gurbel, P.A. Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. Pharm. Res. 23, 2691-2708 (2006).
36. Tantry, U.S., Bliden, K.P. & Gurbel, P.A. Prasugrel. Expert Opin. Investig. Drugs. 15, 1627-1633 (2006).
37. Fugate, S.E. & Cudd, L.A. Cangrelor for treatment of coronary thrombosis. Ann. Pharmacother. 40, 925-930 (2006).
38. Tantry, U.S., Bliden, K.P. & Gurbel, P.A. AZD6140. Expert Opin. Investig. Drugs 16, 225-229 (2007).
39. Jakubowski, J.A. et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br. J. Clin. Pharmacol. 63, 421-430 (2007).
40. Wiviott, S.D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
41. van Giezen, J.J. & Humphries, R.G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31, 195-204 (2005).
42. James, S. et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am. Heart. J. 157, 599-605 (2009).
43. Chackalamannil, S., Ahn, H.S., Xia, Y., Doller, D. & Foster, C. Potent non-peptide thrombin receptor antagonists. Curr. Med. Chem. Cardiovasc. Hematol. Agents 1, 37-45 (2003).
44. Becker, R.C. et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373, 919-928 (2009).
45. Kong, D.F. et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98, 2829-2835 (1998).
46. Chew, D.P., Bhatt, D.L., Sapp, S. & Topol, E.J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103, 201-206 (2001).
47. Schneider, D.J., Taatjes, D.J. & Sobel, B.E. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc. Res. 45, 437-446 (2000).
48. Wakefield, T.W., Myers, D.D., Henke, P.K. Mechanisms of venous thrombosis and resolution. Arterioscler. Thromb. Vasc. Biol. 28, 387-391 (2008).
49. Massberg, S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J. Exp. Med. 196, 887-896 (2002).
50. Croce, K. & Libby, P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr. Opin. Hematol. 14, 55-61 (2007).
51. Myers, D. et al. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb. Haemost. 87, 374-382 (2002).
52. Gross, P.L. & Weitz, J.I. New anticoagulants for treatment of venous thromboembolism. Arterioscler. Thromb. Vasc. Biol. 28, 380-386 (2008).
53. Weitz, JI. Factor Xa or thrombin: is thrombin a better target? J. Thromb. Haemost. (5 suppl. 1), 65-67 (2007).
54. Testa, L., Andreotti, F., Biondi Zoccai, G.G., Burzotta, F., Bellocci, F. & Crea, F. Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients. Int. J. Cardiol. 122, 117-124 (2007).
55. Lee, W.M. et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 28, 351-370 (2005).
56. Ansell, J. Factor Xa or thrombin: is factor Xa a better target? J. Thromb. Haemost. (5 suppl. 1), 60-64 (2007).
57. Furugohri, T. et al. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. Eur. J. Pharmacol. 514, 35-42 (2005).
58. Eriksson, B.I., Quinlan, D.J. & Weitz, J.I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin. Pharmacokinet. 48:1-22 (2009).
59. Eriksson, B.I. et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost. 3, 103-111 (2005).
60. Fisher, W.D. et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb. Haemost. 97, 931-937 (2007).
61. Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J. & Roth, W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos. 36, 386-399 (2008).
62. Stangier, J., Stahle, H., Rathgen, K. & Fuhr, R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin. Pharmacokinet. 47, 47-59 (2008).
63. Eikelboom, J.E. & Weitz, J.I. Dabigatran etexilate for prevention of venous thromboembolism. Thromb. Haemost. 101, 2-4 (2009).
64. Eriksson, B.I. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370, 949-956 (2007).
65. Wolowacz, S.E., Roskell, N.S., Plumb, J.M., Caprini, J.A. & Eriksson, B.I. Eficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb. Haemost. 101, 77-85 (2009).
66. Eriksson, B.I. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358, 2765-2775 (2008).
67. Kakkar, A.K. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372, 31-39 (2008).
68. Turpie, A.G. et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopedic surgery: Effect on symptomatic venous thromboembolism, death and bleeding. Blood 112, 36a. (2008).
69. Lassen, M.R. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776-2786 (2008).
70. Turpie, A.G. et al. Once-daily oral rivaroxaban compared with subcutaneous enoxaparin every 12 hours for thromboprophylaxis after total knee replacement: RECORD4. Blood 112, 35a. (2008).
71. Lassen, M.R., Davidson, B.L., Gallus, A., Pineo, G., Ansell, J. & Deitchman, D. The eficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost. 5, 2368-2375 (2007).
72. Spyropoulos, A.C. Investigational treatments of venous thromboembolism. Expert. Opin. Investig. Drugs 16, 431-440 (2007).
73. Ezekowitz, M.D. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am. J. Cardiol. 100, 1419-1426 (2007).
74. Anand, S.S. & Yusuf, S. Oral anticoagulants in patients with coronary artery disease. J. Am. Coll. Cardiol. 41 (4 suppl. 5), 62S-69S (2003).